In conclusion, our data suggest that selected patients with PAH and cardiovascular comorbidities may derive some benefit from initial PAH combination therapy, as greater improvements were observed in WHO FC, BNP/NT‐pro‐BNP levels and risk status compared to monotherapy. This evidence concerns the gene NPPB and pulmonary arterial hypertension.